Shock
Conditions
Brief summary
This study aims to evaluate the effectiveness of midodrine as an adjuvant to norepinephrine in weaning critically ill patients from vasopressors
Interventions
DRUGWeaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine
• Patients in group I will receive midodrine (10 mg orally every 8 hours) in addition to administered concurrently with ongoing intravenous norepinephrine after being on norepinephrine for more than 24 hrs.
DRUGWeaning critically ill patients from norepinephrine without use of midodrine as an adjuvant
Patients in group II with ongoing intravenous norepinephrine only
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with refractory hypotension on an intravenous vasopressor for more than 24 h but deemed clinically stable. * Patients on noradrenaline support \<10 μg/min
Exclusion criteria
* Known allergy to midodrine. * Severe shock state, as evidenced by multiple vasopressor infusions or high vasopressor requirement (i.e. noradrenaline \>10 μg/min) * Patients with severe organic heart disease (e.g., heart failure, sever aortic stenosis), pregnancy, thyrotoxicosis or pheochromocytoma. * Those with no enteral route available.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| follow up of critically ill patients on vasopressors | 48 hours | time of weaning from intravenous vasopressor (norepinephrine) |
Countries
Egypt
Outcome results
None listed